Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.

NCT03115138 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped investigator choice

Conditions

Glioblastoma
Molecular Disease

Interventions

OTHER: Correlation between molecular anomalies of the primary tumor and circulating tumor DNA

Sponsor

Centre Hospitalier Universitaire, Amiens